论文部分内容阅读
目的:探讨肝素结合样表皮生长因子(HB-EGF)、C-erbB-2癌基因在卵巢癌组织中的表达及其临床意义。方法:选取2010年1月~2012年12月间于我院因卵巢肿瘤行手术治疗的患者60例,其中良性卵巢瘤、交界性卵巢瘤、上皮性卵巢癌各20例,取卵巢组织,采用组织流式细胞术检测卵巢组织中HB-EGF、C-erbB-2的表达情况。结果:HB-EGF、C-erbB-2在卵巢癌组织中阳性细胞率显著高于良性卵巢瘤,组间比较差异有统计学意义(P<0.05),且两种因子在卵巢癌Ⅲ~Ⅳ期组织中表达高于Ⅰ~Ⅱ期(P<0.05)。结论:HB-EGF、C-erbB-2检测可作为卵巢良恶性肿瘤鉴别诊断的辅助指标,且与卵巢癌病情严重程度呈正相关,二者联合检测可更准确反映卵巢癌病情。
Objective: To investigate the expression and clinical significance of heparin-binding-like epidermal growth factor (HB-EGF) and C-erbB-2 oncogene in ovarian cancer. Methods: From January 2010 to December 2012 in our hospital for surgical treatment of ovarian tumors in patients with 60 cases, including benign ovarian tumors, borderline ovarian tumors, epithelial ovarian cancer in 20 cases, the use of ovarian tissue The expression of HB-EGF and C-erbB-2 in ovarian tissue was detected by flow cytometry. Results: The positive rate of HB-EGF and C-erbB-2 in ovarian cancer was significantly higher than that in benign ovarian cancer (P <0.05), and the difference was statistically significant The expression in stage was higher than that in stage Ⅰ ~ Ⅱ (P <0.05). Conclusion: The detection of HB-EGF and C-erbB-2 can be used as auxiliary indexes in the differential diagnosis of benign and malignant ovarian tumors and positively correlated with the severity of ovarian cancer. The combined detection of HB-EGF and C-erbB-2 can reflect the status of ovarian cancer more accurately.